Olanzapine
- Generic Name
- Olanzapine
- Brand Names
- Lybalvi, Olazax, Symbyax, Zalasta, Zypadhera, Zyprexa, Olanzapine Glenmark Europe, Olanzapine Apotex, Olanzapine Teva, Olazax Disperzi, Olanzapine Mylan, Zyprexa Velotab, Olanzapine Glenmark
- Drug Type
- Small Molecule
- Chemical Formula
- C17H20N4S
- CAS Number
- 132539-06-1
- Unique Ingredient Identifier
- N7U69T4SZR
- Background
Olanzapine is a thienobenzodiazepine classified as an atypical or second-generation antipsychotic agent. The second-generation antipsychotics were introduced in the 90s and quickly gained traction due to their impressive efficacy, reduced risk for extrapyramidal side effects and reduced susceptibility to drug-drug interactions. Olanzapine very closely resemb...
- Indication
Olanzapine was initially used orally and intramuscularly for the chronic treatment of schizophrenia in patients over 13 years old and other psychiatric disorders such as bipolar I disorder including mixed or manic episodes.
...
- Associated Conditions
- Acute Agitation, Bipolar 1 Disorder, Bipolar Disorder With Manic or Mixed Episodes, Delirium, Delusional Parasitosis, Depressive Episodes, Gilles de la Tourette's Syndrome, Major depressive disorder, recurrent episode, Mixed manic depressive episode, Post Traumatic Stress Disorder (PTSD), Psychosis, Schizophrenia, Acute Manic episode
- Associated Therapies
- -
Cannabidiol as a Different Type of an Antipsychotic: Drug Delivery and Interaction Study
- Conditions
- Interventions
- First Posted Date
- 2014-01-31
- Last Posted Date
- 2018-03-08
- Lead Sponsor
- Central Institute of Mental Health, Mannheim
- Target Recruit Count
- 74
- Registration Number
- NCT02051387
- Locations
- 🇩🇪
Dept. of Pharmacology, University of Cologne, Cologne, NRW, Germany
🇩🇪Central Institute of Mental Health, Mannheim, BW, Germany
Atypical Antipsychotics for Continuation and Maintenance Treatment After an Acute Manic Episode
- Conditions
- Interventions
- First Posted Date
- 2013-11-06
- Last Posted Date
- 2015-11-20
- Lead Sponsor
- University of British Columbia
- Target Recruit Count
- 159
- Registration Number
- NCT01977300
- Locations
- 🇨🇦
University of British Columbia, Vancouver, British Columbia, Canada
Assessment and Comparison of Metabolic Changes in Non-psychotic Adults Taking Iloperidone or Olanzapine or Placebo
- First Posted Date
- 2013-08-12
- Last Posted Date
- 2017-03-20
- Lead Sponsor
- New York State Psychiatric Institute
- Target Recruit Count
- 31
- Registration Number
- NCT01920802
- Locations
- 🇺🇸
New York State Psychiatric Institute, New York, New York, United States
A Study of ALKS 3831 in Adults With Schizophrenia
- Conditions
- Interventions
- First Posted Date
- 2013-07-19
- Last Posted Date
- 2021-10-06
- Lead Sponsor
- Alkermes, Inc.
- Target Recruit Count
- 347
- Registration Number
- NCT01903837
- Locations
- 🇨🇿
Alkermes Investigational Site, Praha, Czechia
Comparative Efficacy and Acceptability of Antimanic Drugs in Acute Mania
- Conditions
- Interventions
- First Posted Date
- 2013-07-08
- Last Posted Date
- 2015-03-17
- Lead Sponsor
- Guiyun Xu
- Target Recruit Count
- 120
- Registration Number
- NCT01893229
- Locations
- 🇨🇳
Guangzhou Psychiatric Hospital, Guangzhou, Guangdong, China
Olanzapine Compared to Lamotrigine in the Prevention of Depressive Episode in the Patients With Bipolar Disorder
- First Posted Date
- 2013-05-29
- Last Posted Date
- 2013-05-29
- Lead Sponsor
- Tri-Service General Hospital
- Target Recruit Count
- 60
- Registration Number
- NCT01864551
- Locations
- 🇨🇳
Tri-Service General Hospital, Taipei, Taiwan
A Study of Olanzapine and Fluoxetine for Treatment-resistant Depression
- Conditions
- Interventions
- First Posted Date
- 2012-09-19
- Last Posted Date
- 2019-10-09
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 176
- Registration Number
- NCT01687478
- Locations
- 🇨🇳
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Xinxiang, China
A Pilot Study on the Efficacy and Safety of Olanzapine in Gastroparesis
- First Posted Date
- 2012-06-22
- Last Posted Date
- 2019-09-10
- Lead Sponsor
- University of Michigan
- Target Recruit Count
- 3
- Registration Number
- NCT01625923
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸University of Michigan, Ann Arbor, Michigan, United States
A Study of the Efficacy and Safety of Asenapine in Participants With an Acute Exacerbation of Schizophrenia (P05688)
- Conditions
- Interventions
- First Posted Date
- 2012-06-12
- Last Posted Date
- 2024-06-18
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 360
- Registration Number
- NCT01617187
Long-Term Safety Extension Trial of Asenapine in Schizophrenia Participants Who Completed Protocol P05688 (P05689)
- Conditions
- Interventions
- First Posted Date
- 2012-06-12
- Last Posted Date
- 2015-05-27
- Lead Sponsor
- Forest Laboratories
- Target Recruit Count
- 105
- Registration Number
- NCT01617200
- Locations
- 🇺🇸
Forest Investigative Site 2001, Austin, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.